$MRSH

Yates Lloyd M sold $2.1M of MRSH

Yates Lloyd M sold 12,000 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $175.65 ($2.11M total) on 2026-07-23.

Original reporting
SEC EDGAR · Yates Lloyd M
Published Jul 24, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRSH
Neutral
medium confidence
Mentioned
$MRSH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note the sale for sentiment monitoring, but there is no accompanying company-specific catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context or repeated sales, signal quality is low.

Relevance 6/10Novelty 3/10Timing: Filed 2026-07-24, discloses sale executed 2026-07-23.

Background

The article is a SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralMedium confidence
Context

Marsh & McLennan director Yates Lloyd M sold 12,000 shares on 2026-07-23 at $175.65, totaling $2.11M, per Form 4.

Expected impact

Likely limited near-term impact; treat as routine insider liquidity unless follow-on filings suggest broader selling.

Evidence & confidence

The article provides a single Form 4 sale with no 10b5-1 plan and no accompanying company-specific news, so the incremental trading signal is modest.

Market effects

No sector read-across is provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “mechanical” selling, but the filing alone does not establish intent or future sales.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Yates Lloyd M

    Director who sold 12,000 shares on 2026-07-23.

Related articles

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%

$MRSHHighAI 9/10

Marsh & McLennan Companies (NYSE:MRSH) Stock Price Down 13.1% After Analyst Downgrade

Marsh & McLennan (NYSE:MRSH) fell 13.1% mid-day Wednesday after Piper Sandler cut its price target to $182 from $190 and kept a neutral rating. Shares traded as low as $180.97 and last at $160.70, after closing $185.00; volume rose to 3.04M. The article also cites recent analyst target changes and April 16 quarterly results: $3.29 EPS vs $3.21 consensus on $7.30B revenue.